All In Biotech

Drug Trial Radar · NCT06990880

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5458514 PSMA Targeting T Cell Engager Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

Oct 26, 2027

Study completion Aug 9, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

Conditions

  • Neoplasms, Prostate

Interventions

  • GSK5458514Drug

    GSK5458514 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs) during DLT observation periodTime frame: Up to 28 days
  2. Number of participants with adverse events (AEs), serious adverse events (SAEs), by SeverityTime frame: Up to approximately 29 months
  3. Number of participants with AEs leading to dose modificationsTime frame: Up to approximately 29 months

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona · Recruiting

  • GSK Investigational Site

    Denver, Colorado · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Rochester, Minnesota · Recruiting

  • GSK Investigational Site

    East Brunswick, New Jersey · Recruiting

  • GSK Investigational Site

    Nashville, Tennessee · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Lyon, France · Recruiting

  • GSK Investigational Site

    Villejuif, France · Recruiting

  • GSK Investigational Site

    Kanagawa, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Badajoz, Spain · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Málaga, Spain · Recruiting

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.